On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.
Back in August, the CheckRare Brief covered the drug supply disruptions affecting patients receiving Sanofi’s enzyme replacement therapies. The problems centered around Sanofi’s Waterford, Ireland, manufacturing facility. The FDA had inspected the site in January and issued a warning letter in June citing deficiencies in its quality systems.
In the months that followed, patients in several countries experienced delays in accessing treatments for rare diseases, including Pompe, Fabry, and Gaucher.
Since then, Sanofi has issued additional supply updates that may disrupt supply for some of those therapies into 2027 while a new manufacturing site get build. In addition, the company recently disclosed a potential longer-term supply shortfall for Xenpozyme, its treatment for ASMD.
Topics covered in this conversation include
- Ongoing supply challenges
- The anticipated Xenpozyme shortfall from mid-2027
- Protecting access to therapies for the most vulnerable
- Preventing future disruptions
References
Sanofi press release (Aug 17) about shortage
